Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  EntreMed Inc    ENMD   US29382F2020

ENTREMED INC (ENMD)

0
 SummaryQuotesChart AnalysisNewsCalendarCompany 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/16/2014 04/17/2014 04/21/2014 04/22/2014 04/23/2014 Date
1.92(c) 1.87(c) 1.96(c) 1.97(c) 1.94(c) Last
5 634 11 742 18 057 98 372 5 553 Volume
+2.67% -2.60% +4.81% +0.51% -1.52% Change
More quotes
Company
EntreMed, Inc. is a clinical-stage pharmaceutical company developing a new generation of multi-mechanism drugs for the treatment of cancer and inflammatory diseases. Its drug candidate, ENMD 2076, which is an Aurora A and angiogenic kinase inhibitor for the treatment of cancer. The company was... 
Sector
Calendar
05/20Earnings Release
More about the company
Chart ENTREMED INC
Duration : Period :
EntreMed Inc Technical Analysis Chart | ENMD | US29382F2020 | 4-Traders
Full-screen chart
Latest news on ENTREMED INC
03/26 ENTREMED : Reports 2013 Fourth Quarter And Full Year Financial Results
03/21 ENTREMED : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESUL..
03/21 ENTREMED : Results of Operations and Financial Condition (form 8-K)
03/13 ENTREMED : "Method for the Treatment of Multiple Sclerosis" in Patent Applicatio..
2013 ENTREMED INC : EntreMed Begins Phase 2 Trial For ENMD-2076 In Ovarian Clear Cell..
2013 EntreMed Begins Phase 2 Trial For ENMD-2076 In Ovarian Clear Cell Carcinomas
2013 ENTREMED INC FILES (8-K) Disclosing Results of Operations and Financial Condi..
2013 ENTREMED INC : FILES (8-K) Disclosing Results of Operations and Financial Condit..
2013 ENTREMED INC : EntreMed Reports Third Quarter 2013 Financial Results
2013 ENTREMED INC : EntreMed Commences Phase 2 Trial For ENMD-2076 In Ovarian Clear C..
2013 ENTREMED INC : Data Presented For ENMD-2076 In Xenograft Models Of Human Hepatoc..
2013 ENTREMED INC : Data Presented For ENMD-2076 In Preclinical Models Of Triple-Nega..
More news
Comments 
Advertisement
Dynamic quotes  
ON
| OFF